Filana Gets FDA Lift Of Clinical Hold On Simufilam For TSC-Related Epilepsy; Pre-market Stock Down

(RTTNews) - Filana Therapeutics, Inc. (FLNA), a biotechnology company focused on targeted therapies on filamin A protein, on Tuesday announced that the U.S. Food and Drug Administration has lifted the clinical hold on its Investigational New Drug (IND) application for Simufilam.